Trial Profile

Multicenter, Randomized, Double-blind Placebo-controlled, Crossover Study to Investigate Effects of V117957 in Female Subjects With Overactive Bladder Syndrome

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Jan 2025 According to an Imbrium Therapeutics media release, company announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel investigational treatment sunobinop in patients with overactive bladder syndrome (OAB)
07 Jan 2025 Results published in the Imbrium Therapeutics media release
09 Jul 2024 According to an Imbrium Therapeutics media release, company achieved last patient last visit in its Phase 1b study of the investigational drug sunobinop as a potential treatment for overactive bladder syndrome (OAB).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com